Determination of replacement and suppressive doses of thyroxine. 1990

K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
Department of Orthopedics, University of Miami School of Medicine, Florida.

Suppression daily doses of thyroxine (T4) were determined and the daily amounts of T4 required to replace T4 were established in 217 hypothyroid patients. Patients with Hashimoto's thyroiditis treated daily with 2-3 micrograms/kg lean body mass or 1-2 micrograms/kg body weight T4 had normal serum thyrotrophin (TSH) concentrations, normal response to TSH-releasing hormone (TRH) and normal systolic time intervals but doses higher than 3 micrograms/kg lean body mass or 2 micrograms/kg body weight decreased serum TSH concentrations, with no response to TRH and systolic time intervals typical of hyperthyroidism. In 13/32 (41%) hypothyroid patients with Graves' disease following 131I and/or surgery, the daily T4 replacement dose was similar to that in Hashimoto's thyroiditis patients but in 12 (38%) patients daily doses of 2-3 micrograms/kg lean body mass or 1-2 micrograms/kg body weight T4 increased serum T4 and suppressed TSH levels, and in six (9%) lower doses were required to control hypothyroidism. The T4 suppression dose for patients with thyroid cancer was more than 3 micrograms/kg lean body mass or 2 micrograms/kg body weight, whereas approximately 30% of non-toxic nodular goitre patients required less than 3 micrograms/kg lean body mass. It is concluded that replacement or suppression doses of T4 should be individually determined and that different criteria should be applied for their calculation depending on the thyroid abnormality.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006044 Goiter, Nodular An enlarged THYROID GLAND containing multiple nodules (THYROID NODULE), usually resulting from recurrent thyroid HYPERPLASIA and involution over many years to produce the irregular enlargement. Multinodular goiters may be nontoxic or may induce THYROTOXICOSIS. Nodular Goiter,Goiters, Nodular,Nodular Goiters
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013964 Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. Cancer of Thyroid,Thyroid Cancer,Cancer of the Thyroid,Neoplasms, Thyroid,Thyroid Adenoma,Thyroid Carcinoma,Adenoma, Thyroid,Adenomas, Thyroid,Cancer, Thyroid,Cancers, Thyroid,Carcinoma, Thyroid,Carcinomas, Thyroid,Neoplasm, Thyroid,Thyroid Adenomas,Thyroid Cancers,Thyroid Carcinomas,Thyroid Neoplasm
D013965 Thyroidectomy Surgical removal of the thyroid gland. (Dorland, 28th ed) Thyroidectomies

Related Publications

K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
August 1978, The Western journal of medicine,
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
January 1977, Acta medica Scandinavica,
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
January 2001, Wiadomosci lekarskie (Warsaw, Poland : 1960),
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
April 1968, The Journal of clinical investigation,
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
April 1994, The Journal of clinical endocrinology and metabolism,
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
January 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
February 1998, Clinical endocrinology,
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
October 1993, The New Zealand medical journal,
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
January 2001, Wiadomosci lekarskie (Warsaw, Poland : 1960),
K Banovac, and S A Carrington, and S Levis, and M D Fill, and M S Bilsker
July 2018, Endocrine,
Copied contents to your clipboard!